Total Funding
48
36
Total FundingEquity Crowdfunding raised
Growth Score
-4 pts
Heat Score
-13 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
96118
RS BioTherapeutics is a research, development, and commercialization company focused on pulminary diseases.
- Justin Molignoni: Co-Founder and CSO
- Michael Guzman Diaz: Chief Of Staff
About the Company
Founded in 2021, the mission of RS BioTherapeutics is to develop life-changing medicines for the millions of people suffering from deadly lung diseases characterized by pulmonary inflammation. RS BioTherapeutics is developing a first-in-class, steroid-free, multi-targeted immune modulator (RSBT-001) with Chronic Obstructive Pulmonary Disease
(COPD), Idiopathic Pulmonary Fibrosis (IPF), and Pulmonary Arterial Hypertension (PAH) as potential first indications. RS BioTherapeutics owns the exclusive, global license for RSBT-001 and is projecting filing an Investigational New Drug Application for RSBT-001 and initiating human trials in late 2026.
